Summary We have established a reliable method to induce invasive and non-invasive carcinomas in the heterotopically transplanted urinary bladder of rats by repeated injection of N-methyl-N-nitrosourea (MNU). and examined the alterations of the ras oncogenes and ras oncogene product (p21) in the induced tumours. The incidence of muscle-invasive carcinomas was proportional to the total dose of MNU. When 5, 6 or 12 doses of MNU were used, muscle invasive carcinomas developed in 22, 58 or 45% of animals, respectively, after a mean observation period, respectively, of 54 ± 9, 45 ± 13 and 38 ± 3 weeks. Human bladder cancer can be divided into two types; a majority of them are low-grade papillary carcinomas only superficially invasive, whereas as many as 20% of tumours are deeply invasive potentially lethal carcinomas (Kaye & Lange, 1982; Brawn, 1982) . When human bladder cancers were tested for transforming activity using NIH3T3 cells, activated H-ras was demonstrated in approximately 10% of randomly selected tumours (Fujita et al., 1984; Fujita et al., 1985) , and there was no correlation between H-ras activation and the degree of invasiveness of tumours. As in human carcinomas, the rate of ras oncogene activation is infrequent in carcinogen-induced rat bladder carcinomas (Fujita et al., 1988; Debiec-Rychter et al., 1989) . Thus the significance of ras gene alterations in the development of urinary bladder cancer in general and of deeply invasive carcinoma in particular remains unclear. Though several models are available for the induction of rat urinary bladder cancer, the frequency of deeply invasive carcinoma is low and requires an extended period of observation (Kunze, 1979) . In this study, the heterotopically transplanted rat urinary bladder system (HTB) was used for the induction of urinary bladder carcinomas. It was developed in our laboratory to study the role of urine on bladder carcinogenesis (Oyasu et al., 1976; Oyasu et al., 1978) . The system is also suited to test the effect of topically applied carcinogen because urinary tract infection and subsequent calculus formation, the two common complications which frequently occur after repeated intravesical administration of test substances can be avoided with the HTB system. Though useful for testing direct effects of test compound on the bladder mucosa, disadvantages include meticulous care of the HTB to avoid infection and the fact that periodic spontaneous emptying (micturition) cannot be expected to occur. We had two objectives, to establish a reliable method to induce non-invasive and deeply invasive carcinomas after MNU administration and to examine the alterations of the ras genes and ras gene product (p21) in these tumours.
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Materials and methods
Induction of carcinomas in heterotopically transplanted bladder (HTB) The HTB system was established in male Fischer 344 rats by the published method (Oyasu et al., 1976; Oyasu et al., 1978; Babaya et al., 1982) . In brief, a bladder taken aseptically from donor rat was connected to a reservoir (Babaya et al., 1982) through an intervening silastic tubing. The bladderreservoir unit was then transplanted into a syngeneic recipient in such a way that the bladder portion was placed within the gluteal muscle and the reservoir portion was in the dorsal subcutaneous tissue. The skin incision was closed with metal clips. Four weeks after transplantation of urinary bladder, recipients in the first two groups received instillation into HTBs 0.5 mg of N-methyl-N-nitrosourea (MNU) (ICN Pharmaceutical, NJ) dissolved in 0.5 ml of physiologic saline once a week for 2 weeks (Figure 1 ). Since the HTB system is a blind pouch, the injected material will not be lost by micturition, but will be absorbed through the mucosa. Therefore MNU will be taken up by the urothelial cells exerting genotoxic effects. The compound is alkali labile, and carcinogenic effects on other organs are not expected to take place. After 20 weeks, group 2 rats received 0.5 mg of MNU for three consecutive weeks. Group 3 and 4 rats received 0.5 mg of MNU once a week for 6 weeks. After 16 weeks, group 4 rats received additional 6-weekly doses of 0.5 mg MNU. Ten weeks after bladder transplantation, all HTBs received 0.5 ml of normal sterilised rat urine once a week until termination of the experiment. The injected urine is expected to be completely absorbed in 48 h (Hirao et al., 1980) . Rats were allowed to live until a majority of the HTBs in the group became markedly distended and the bladder aspirate haemorrhagic. These changes were indicative of tumour development (Oyasu et al., 1976; Oyasu et al., 1978) . When large, tumours were divided into four parts, one part used for transplantation in nude mice, a second for explant culture, a third for storage at -80°C for DNA extraction and the fourth for light microscopic examination. Small tumours were submitted for histologic examination only. Tumours were classified by grade, stage, and histologic type (Oyasu et al., 1987 ) (see also and 42°C) with 32P-labelled probes (3.0 x 106 c.p.m.) obtained by nick translation (Rigby et al., 1977) . The probes used were v-H-ras, v-K-ras, v-myc (Oncor, Gaitherburg, MD), p5lC-and pHER A64-1 (ATCC, Rockville, MD).
Immunoblot
Protein was extracted from tumour cells (Meyers et al., 1989) and ras p21 was concentrated by immunoprecipitation (Finkel et al., 1984) with rat monoclonal antibody Y13-259 (Oncogene Science, Inc., Manhasset, NY), which recognises the products of normal or activated H-ras, K-ras and c-N-ras (Furth et al., 1982) . Immunoprecipitates were collected by centrifugation, washed, boiled in sample buffer, and resolved by SDS-polyacrylamide electrophoresis (Laemmli, 1970) . Following transfer to nitrocellulose membranes (Towbin et al., 1979) and subsequent blocking with bovine serum albumin in PBS, membranes were incubated with the following antibodies; Y13-259, mouse monoclonal antibodies recognising the twelfth position substitutions with valine (DWP), arginine (R256), glutamic acid (E184) (DuPont, Boston, MA) or classmatched myeloma control proteins MOPC-141 (IgG2b) (Litton Bionetics, Charleston, SC) and MOPC-21 ((IgGl) (Cappel, West Chester, PA). As positive controls, T24 human bladder cancer cells (glycine to valine at codon 12), S2-721 cells (NIH3T3 cells transformed by a rat H-ras oncogene activated by a GGA -> GAA mutation in codon 12, encoding glutamic acid) and 118-413 cells (NIH3T3 cells transformed by a human K-ras oncogene activated by a GGT -*CGT mutation in codon 12, encoding arginin) were used. Membranes were then incubated with either rabbit anti-rat horseradish peroxidase or biotinylated anti-mouse horseradish peroxidase, and then incubated with diaminobenzidine substrate to complete the reaction.
Results

Incidence of carcinomas in HTBs
The treatment with 12 doses (group 4) yielded the highest tumour incidence (100%) despite shorter study period (38 ± 3 0 1 2 5 aMNU (0.5 mg) was instilled into heterotopically transplanted bladder (HTB) via its attached reservoir once a week for two (group 1), five (group 2), six (group 3) or 12 (group 4) doses. In groups 2 and 4, the second series of MNU treatment began 15 weeks after the completion of the first series. bT, transitional; Sqd, squamoid; Sq, squamous.
The number denotes the number of rats with indicated type of bladder tumours. CpO, 1, 2 and 3 respectively refers to the tumours limited to the mucosa, extension to lamina propria, tunica muscularis propria and perivesical tissue. Table I ). The MNU dose of more than 3 mg was effective in inducing deeply invasive carcinomas (P2 and 3) and their incidences in groups 3 (0.5 mg x 6) and 4 (0.5 mg x 12) were, respectively, seven of 12 and nine of 20. The tumours observed in group 1 (0.5 mg x 2) were all small and non-invasive. These results together with our previous findings (Oyasu et al., 1987) samples developed foci. DNA derived from these foci were subjected to Southern blot analysis using ras gene probes. Neither K-ras nor N-ras probe detected DNA fragments other than the endogenous mouse fragments (data not shown), but one of the seven transformants (NI-10) contained additional DNA bands that hybridised with the H-ras probe (Figure 2, lane b) . NI-10 was derived from a grade I PO transitional cell carcinoma. Amplification of H-ras, K-ras, myc and EGF receptor gene was examined in ten primary tumours (five invasive and five non-invasive) and five transplants (two invasive and three non-invasive) and two cell lines . Of these samples, nine primary tumours and three transplants were also used in DNA transfection assay. No amplification was demonstrated in any sample including NI-10, which contained activated H-ras gene.
Detection of activated ras p21 by immunoblot All of the 18 tumour samples tested demonstrated p21 at various densities (Figure 3) . Seven of 18 carcinomas contained activated ras p21 reactive with monoclonal antibody El 84 which specifically recognises the mutation from glycine to glutamic acid at codon 12. The protein extract of NI-10 which was shown to contain activated H-ras gene by Southern blot analysis also expressed activated ras p21. No reactivity was demonstrated with monoclonal antibodies DWP and R256 or negative controls MOPC-21 and 141 (data not shown).
Discussion
In the present study, we not only confirmed the previous observation that the frequency of deeply invasive carcinomas was proportional to MNU dose, but that the highest dose schedule (0.5 mg x 12) was able to shorten the induction period considerably. The tumour implants in nude mice remained relatively stable in their phenotypic expression after repeated passages.
One mechanism of activation of ras genes is induction of mutation at positions 12, 13 or 61 (Tabin et al., 1982; Reddy et al., 1982; Bos et al., 1985; Yuasa et al., 1983) . In MNUinduced rat mammary carcinomas, the H-ras-1 became activated by single amino acid substitution at the twelfth codon, encoding glutamic acid instead of glycirie (Sukumar et al., 1983) . To clarify the effect of MNU on the ras p21 in MNU-induced rat bladder carcinomas, we examined the reactivity of ras p21 with antibodies which were raised against synthetic peptides showing substitution at codon 12 of ras p21 from glycine to valine, glutamic acid, or arginine. Specificity of these monoclonal antibodies has been adequately demonstrated (Carney et al., 1986; Pullano et al., 1989; Azuma et al., 1990) . Immunoblot analysis demonstrated that seven of 18 carcinomas tested contained activated ras p21 with substitution with glutamic acid. Of the nine tumours which were subjected also to DNA transfection assay, three showed twelfth codon mutation and yet in only one of these (NI-10) ras gene activation was demonstrable by Southern blot hybridisation perhaps due to low sensitivity of the assay. It has been observed that although human H-ras-1 genes mutated at codon 12, encoding glutamic acid in place of glycine, generated transformants by transfection assay, the cells displayed a less striking change in morphology as compared to those generated by mutated ras genes which encoded valine (Seeburg et al., 1984) . Since rare 'spontaneous' carcinoma occurred in urine-treated HTB without carcinogen treatment (Ozono et al., 1983) there is a possibility that ras mutation seen in some tumours is unrelated to MNU treatment.
In conclusion, our data indicate that approximately onehalf of non-invasive and invasive carcinomas induced by MNU contain activated ras oncogenes or oncogene product p21, but that their expression cannot be correlated to the aggressiveness of tumours. Our data are consistent with the previous observation that H-ras oncogenes are activated by MNU during the initiation of rat mammary carcinogenesis (Sukumar et al., 1983) .
